Evidence map›Paper›PMID 36808595›Full record

ReviewCurrent urology reports2023

Exploring the Use of Artificial Intelligence in the Management of Prostate Cancer.

Timothy N Chu, Elyssa Y Wong, Runzhuo Ma, Cherine H Yang, Istabraq S Dalieh, Andrew J Hung

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current urology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. AI-accelerated prostate MRI: a systematic review.The British journal of radiology · 2024
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. ChatGPT for medical applications and urological science.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Timothy N ChuCenter for Robotic Simulation & Education, Department of Urology, USC Institute of Urology, University of Southern California, Catherine & Joseph Aresty1441 Eastlake Avenue Suite 7416, Los Angeles, CA, 90089, USA.
Elyssa Y WongCenter for Robotic Simulation & Education, Department of Urology, USC Institute of Urology, University of Southern California, Catherine & Joseph Aresty1441 Eastlake Avenue Suite 7416, Los Angeles, CA, 90089, USA.
Runzhuo MaCenter for Robotic Simulation & Education, Department of Urology, USC Institute of Urology, University of Southern California, Catherine & Joseph Aresty1441 Eastlake Avenue Suite 7416, Los Angeles, CA, 90089, USA.
Cherine H YangCenter for Robotic Simulation & Education, Department of Urology, USC Institute of Urology, University of Southern California, Catherine & Joseph Aresty1441 Eastlake Avenue Suite 7416, Los Angeles, CA, 90089, USA.
Istabraq S DaliehCenter for Robotic Simulation & Education, Department of Urology, USC Institute of Urology, University of Southern California, Catherine & Joseph Aresty1441 Eastlake Avenue Suite 7416, Los Angeles, CA, 90089, USA.
Andrew J HungCenter for Robotic Simulation & Education, Department of Urology, USC Institute of Urology, University of Southern California, Catherine & Joseph Aresty1441 Eastlake Avenue Suite 7416, Los Angeles, CA, 90089, USA. andrew.hung@med.usc.edu.ORCID http://orcid.org/0000-0002-7201-6736

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to explore the current state of research on the use of artificial intelligence (AI) in the management of prostate cancer. We examine the various applications of AI in prostate cancer, including image analysis, prediction of treatment outcomes, and patient stratification. Additionally, the review will evaluate the current limitations and challenges faced in the implementation of AI in prostate cancer management. RECENT

findingsRecent literature has focused particularly on the use of AI in radiomics, pathomics, the evaluation of surgical skills, and patient outcomes. AI has the potential to revolutionize the future of prostate cancer management by improving diagnostic accuracy, treatment planning, and patient outcomes. Studies have shown improved accuracy and efficiency of AI models in the detection and treatment of prostate cancer, but further research is needed to understand its full potential as well as limitations.

Indexed as

Artificial IntelligenceProstatic NeoplasmsHumansImage Processing, Computer-AssistedMaleArtificial intelligenceMachine learningPathomicsProstate cancerRadiomics

Identifiers

PMID36808595
PMCPMC10090000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.